These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32588254)

  • 21. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
    Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
    Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responsiveness of the anxiety/depression dimension of the 3- and 5-level versions of the EQ-5D in assessing mental health.
    Crick K; Al Sayah F; Ohinmaa A; Johnson JA
    Qual Life Res; 2018 Jun; 27(6):1625-1633. PubMed ID: 29516342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How does the EQ-5D-Y Proxy version 1 perform in 3, 4 and 5-year-old children?
    Verstraete J; Lloyd A; Scott D; Jelsma J
    Health Qual Life Outcomes; 2020 May; 18(1):149. PubMed ID: 32448278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
    Sobue Y; Watanabe E; Lip GYH; Koshikawa M; Ichikawa T; Kawai M; Harada M; Inamasu J; Ozaki Y
    Heart Vessels; 2018 Apr; 33(4):403-412. PubMed ID: 29067492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hospital variation in patient-reported outcomes at the level of EQ-5D dimensions: evidence from England.
    Gutacker N; Bojke C; Daidone S; Devlin N; Street A
    Med Decis Making; 2013 Aug; 33(6):804-18. PubMed ID: 23633030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in health-related quality of life of Chinese populations measured by the EQ-5D-3 L: a comparison of the 2008 and 2013 National Health Services Surveys.
    Yao Q; Liu C; Zhang Y; Xu L
    Health Qual Life Outcomes; 2019 Mar; 17(1):43. PubMed ID: 30866953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China.
    Lyu S; Yu L; Tan H; Liu S; Liu X; Guo X; Zhu J
    BMC Cardiovasc Disord; 2019 Sep; 19(1):209. PubMed ID: 31477021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective.
    Whalley D; Globe G; Crawford R; Doward L; Tafesse E; Brazier J; Price D
    Health Qual Life Outcomes; 2018 Aug; 16(1):160. PubMed ID: 30075729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
    Sartipy U; Dahlström U; Fu M; Lund LH
    JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The EQ-5D in alcohol dependent patients: relationships among health-related quality of life, psychopathology and social functioning.
    Günther O; Roick C; Angermeyer MC; König HH
    Drug Alcohol Depend; 2007 Jan; 86(2-3):253-64. PubMed ID: 16930855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction.
    Teng TK; Tay WT; Dahlstrom U; Benson L; Lam CSP; Lund LH
    Int J Cardiol; 2018 Mar; 254():203-209. PubMed ID: 29407092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
    Löfman I; Szummer K; Dahlström U; Jernberg T; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1606-1614. PubMed ID: 28371075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The EQ-5D: a new tool for studying clinical outcomes in chronic rhinosinusitis.
    Remenschneider AK; D'Amico L; Gray ST; Holbrook EH; Gliklich RE; Metson R
    Laryngoscope; 2015 Jan; 125(1):7-15. PubMed ID: 24729050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in health-related quality of life (EQ-5D) dimensions associated with community-based musculoskeletal physiotherapy: a multi-centre analysis.
    Caplan N; Robson H; Robson A; Kelly M; Wilkes G
    Qual Life Res; 2018 Sep; 27(9):2373-2382. PubMed ID: 29948600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.
    Damman K; Solomon SD; Pfeffer MA; Swedberg K; Yusuf S; Young JB; Rouleau JL; Granger CB; McMurray JJ
    Eur J Heart Fail; 2016 Dec; 18(12):1508-1517. PubMed ID: 27427441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study.
    Freiberg MS; Chang CH; Skanderson M; Patterson OV; DuVall SL; Brandt CA; So-Armah KA; Vasan RS; Oursler KA; Gottdiener J; Gottlieb S; Leaf D; Rodriguez-Barradas M; Tracy RP; Gibert CL; Rimland D; Bedimo RJ; Brown ST; Goetz MB; Warner A; Crothers K; Tindle HA; Alcorn C; Bachmann JM; Justice AC; Butt AA
    JAMA Cardiol; 2017 May; 2(5):536-546. PubMed ID: 28384660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials.
    Mendoza TR; Dueck AC; Shi Q; Ma H; Zhang J; Qian Y; Cleeland CS
    Eur J Pain; 2018 Mar; 22(3):565-571. PubMed ID: 29082574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimally important difference and predictors of change in quality of life in type 2 diabetes: A community-based survey in China.
    Jin X; Liu GG; Gerstein HC; Levine MAH; Guan H; Li H; Xie F
    Diabetes Metab Res Rev; 2018 Nov; 34(8):e3053. PubMed ID: 30064154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved RIDIT statistic approach provides more intuitive and informative interpretation of EQ-5D data.
    Marfak A; Youlyouz-Marfak I; El Achhab Y; Saad E; Nejjari C; Hilali A; Turman J
    Health Qual Life Outcomes; 2020 Mar; 18(1):63. PubMed ID: 32156274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.